Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-HER3 ARC
- Development stage
- Preclinical
- Lead developer
- Actinium Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-HER3 ARC is a preclinical-stage antibody radioconjugate (ARC) being developed through a collaboration between Actinium Pharmaceuticals and AVEO Oncology (a subsidiary of LG Chem). The therapeutic candidate comprises the anti-HER3 monoclonal antibody AT-02, conjugated to the beta-emitting radionuclide Lutetium-177 (177Lu) using a p-SCN-Bn-DOTA chelator. It specifically targets the HER3 (ErbB3) receptor, a member of the epidermal growth factor receptor (EGFR) family that is frequently overexpressed in various solid malignancies, including ovarian, colorectal, prostate, and renal cancers. HER3 overexpression is often linked to poor prognosis and resistance to existing therapies. By binding to HER3 on the surface of cancer cells, 177Lu-HER3 ARC delivers localized, high-energy radiation that induces DNA damage and subsequent apoptosis. Preclinical studies have demonstrated significant reductions in tumor burden in HER3-expressing models compared to standard treatments.
- Other names
- 177Lu-AT-02Lutetium (177Lu) HER3 ARC
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on 177Lu-HER3 ARC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-HER3 ARC.